|
Abstract
Background: Persistent atrial
fibrillation (AF) is difficult to treat. In the
absence of class I or III antiarrhythmic drugs
sinus rhythm is maintained in only 30% of
patients during the first year after electrical
cardioversion (ECV). One of the remodeling
processes induced by AF is fibrosis, which
relates to inducibility and maintenance of AF.
The renin-angiotensin system may play a
important role in this. The aim of this study
was to investigate the role of angiotensin-converting
enzyme (ACE) inhibitor use on efficacy of ECV,
and occurrence of subacute recurrences.
Methods:
One hundred-seven consecutive patients with
persistent AF underwent ECV. In twenty-eight
(26%) patients ACE inhibitors had been started
before initiation of the present episode of AF
('pre-treated' patients).
Results:
ECV was successful in 96% of patients who were
on ACE inhibitors before start of the present
episode of AF compared to 80% of the patients
not pre-treated (p = 0.04). After 1 month of
follow-up 49% of the pre-treated patients and
50% of those not pre-treated with ACE inhibition
were still in sinus rhythm (p=ns). Multivariate
analysis showed that pre-treatment with ACE
inhibitors and a smaller left atrial size were
independent predictors of successful ECV (OR =
5.8, C.I. 1.3–26.1, and OR = 5.6, C.I. 1.2–25.3,
respectively).
Conclusions:
Pre-treatment with ACE inhibitors may improve
acute success of ECV but does not prevend AF
recurrences. Heart Views 2005; 6 (1): 18-23.
|